New Treatment For Childhood Brain Tumours, Tovorafenib, Shows Promising Results With An Efficiency Rate Of 91%!
According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.